Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand Reports Fourth Quarter and Full Year 2016 Financial Results

Read More

Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform

Read More

Reminder: Ligand to Host Analyst Day on February 28th in New York City

Read More

Recent Events

Upcoming Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range